High-throughput strategies for ADME bioanalysis
High-throughput in vitro ADME profiling plays an important role in assessing and mitigating PK liability early in the drug discovery process. In this presentation we will focus on various throughput-enhancing strategies in the LC-MS/MS bioanalysis of both small molecule and peptide NMEs to enable timely and high-quality bioanalytical support for discovery ADME studies.
What you will learn?
- Automated MS/MS method development
- High-speed, multiplexed LC-MS/MS for sample analysis
- Direct online SPE-MS/MS and direction ionization-MS/MS methods
- Software tools for data review and workflow management
- Sample reduction strategies
Who may this interest?
- Discovery bioanalytical scientists
- DMPK/ADME scientists and managers
- LC-MS/MS hardware and software developers
Bristol-Myers Squibb Company
Wilson Shou is Principal Scientist, Discovery Chemistry Platforms at Bristol-Myers Squibb’s R&D site in Wallingford, CT, where he leads a bioanalytical group providing support for the enterprise-wide high-throughput in vitro ADME profiling effort. Dr Shou’s research interests involve the application of mass spectrometry, separation sciences and software/automation tools for the high-throughput bioanalysis of small molecules and peptides in support of lead discovery and optimization. He has authored/coauthored 40 journal articles, four book chapters, and more than 70 podium or poster presentations. He was the guest editor for a special issue of Bioanalysis focusing on discovery bioanalysis in 2012, and also coedited an ebook entitled “Eliminating bottlenecks for efficient bioanalysis: practices and applications in drug discovery and development” in 2014.
Click here to view the Q&A follow-up.
For a full list of other webinars available on Bioanalysis Zone please see here.